Imatinib mesylate suppresses DTH in mice
Group . | Footpad thickness, mm, mean ± SD . |
|---|---|
| 1. Sham injected, not primed | 2.74 ± 0.11 |
| 2. Sham injected, primed | 3.55 ± 0.13 |
| 3. Imatinib mesylate-treated, not primed | 2.80 ± 0.33 |
| 4. Imatinib mesylate-treated, primed | 2.88 ± 0.29 |
Group . | Footpad thickness, mm, mean ± SD . |
|---|---|
| 1. Sham injected, not primed | 2.74 ± 0.11 |
| 2. Sham injected, primed | 3.55 ± 0.13 |
| 3. Imatinib mesylate-treated, not primed | 2.80 ± 0.33 |
| 4. Imatinib mesylate-treated, primed | 2.88 ± 0.29 |
The mean ± SD values refer to the thickness of the footpad of mice, which did not receive (groups 1 and 2) or did receive imatinib mesylate (groups 3 and 4) and were primed (ie, immunized; groups 2 and 4) or not primed by NP-O-Su. All groups were challenged by NP-O-Su 1 day before measurement of the footpad thickness. A 2-tailed t-test comparison for independent groups yielded the following P values: for group 1 versus 2, P = .00006; for group 3 versus 4, P = .21; for group 1 versus 3, P = .702; and for group 2 versus 4, P = .004.